Breaking News Instant updates and real-time market news.

ACHC

Acadia

$27.92

-1.1 (-3.79%)

, ADUS

Addus HomeCare

$83.56

-0.09 (-0.11%)

04:55
08/15/19
08/15
04:55
08/15/19
04:55

RBC Capital to hold a tour

RBC Nashville Healthcare Tour travels throughout Nashville, TN on August 14-15.

ACHC

Acadia

$27.92

-1.1 (-3.79%)

ADUS

Addus HomeCare

$83.56

-0.09 (-0.11%)

AMED

Amedisys

$131.66

-3 (-2.23%)

BKD

Brookdale Senior Living

$8.02

-0.115 (-1.41%)

CYH

Community Health

$2.12

-0.145 (-6.42%)

EHTH

eHealth

$104.49

-5.32 (-4.84%)

EHC

Encompass Health

$61.49

-0.87 (-1.40%)

HCA

HCA Healthcare

$123.22

-4.65 (-3.64%)

SEM

Select Medical

$15.87

-0.23 (-1.43%)

SGRY

Surgery Partners

$6.22

-0.28 (-4.31%)

  • 28

    Aug

  • 04

    Sep

  • 04

    Sep

  • 09

    Sep

  • 10

    Sep

  • 10

    Sep

  • 11

    Sep

  • 16

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 19

    Sep

  • 23

    Sep

  • 13

    Nov

ACHC Acadia
$27.92

-1.1 (-3.79%)

07/31/19
RAJA
07/31/19
DOWNGRADE
Target $45
RAJA
Outperform
Acadia downgraded to Outperform from Strong Buy at Raymond James
Raymond James analyst John Ransom downgraded Acadia Healthcare to Outperform from Strong Buy with a $45 price target. The analyst sees risk to Q3 estimates and ongoing uncertainty in the U.K. following the company's Q2 results.
01/03/19
DBAB
01/03/19
INITIATION
Target $27
DBAB
Hold
Acadia initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Pito Chickering started Acadia Healthcare with a Hold rating and $27 price target. The analyst initiated coverage on Healthcare Facilities with a constructive view saying the sector is "relatively defensive" in slowing business cycles and that company cash flows "provide downside protection in volatile markets."
03/04/19
JEFF
03/04/19
NO CHANGE
Target $40
JEFF
Buy
Acadia guidance acheivable, possibly conservative, says Jefferies
Jefferies analyst Brian Tanquilut said the articulation from Acadia Healthcare management of the bridge from Q4 earnings to 2019 EBITDA guidance underscored the achievability, and possibly even conservatism, of the company's outlook. Additionally, the company's strategic review of the U.K. segment provides a potential positive catalyst in the near-term, said Tanquilut, who has a Buy rating and $40 price target on Acadia shares.
04/23/19
SBSH
04/23/19
NO CHANGE
SBSH
Buy
Citi opens 'Positive Catalyst Watch' on Acadia for potential asset sale
Citi analyst Ralph Giacobbe opened a "Positive Catalyst Watch" on Acadia Healthcare following headlines suggesting the company is seeking a sale of its U.K. business, and specifically the Priory assets for $1.3B. The analyst sees "some optionality," whether it is an outright sale of Priory or select asset sales in the region. He keeps a Buy rating on the shares.
ADUS Addus HomeCare
$83.56

-0.09 (-0.11%)

08/07/19
OPCO
08/07/19
NO CHANGE
Target $91
OPCO
Outperform
Addus HomeCare price target raised to $91 from $80 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Addus HomeCare to $91 from $80 on Q2 beat, as growth prospects remain "strong." The analyst reiterates an Outperform rating on the shares.
06/13/19
RAJA
06/13/19
NO CHANGE
Target $81
RAJA
Outperform
Addus HomeCare price target raised to $81 from $75 at Raymond James
Raymond James analyst John Ransom reiterated an Outperform rating on Addus HomeCare and raised his price target to $81 from $75 following more detail on the recent rate increases in Illinois. In a research note to investors, Ransom says Addus management expects two rate increases of roughly $21M of annualized revenue each effective July 1 of this year and January 1, 2020. Ransom also raised his adjusted EBITDA estimate for 2020 by about $5M, as he removes roughly $3M of EBITDA from unannounced acquisitions for conservatism.
02/04/19
02/04/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Buy from Neutral at Goldman Sachs with analyst Neil Mehta citing better than expected Q4 results to reflect better long-term differential assumptions outside of the U.S., a reduced operating cost outlook given recent trends, higher oil volumes in the Lower 48, Alaska, Asia to reflect project-by-project builds and slightly higher Australia LNG distribution payments up to Conoco. 2. Aon plc (AON) upgraded to Buy from Neutral at MKM Partners with analyst Harry Fong citing the company's "good organic growth" of 6% reported in Q4 as well as its "very strong" free cash flow generation. 3. Intercept (ICPT) upgraded to Strong Buy from Outperform at Raymond James with analyst Steven Seedhouse citing his "unusually high amount of conviction in REGENERATE" trial data, noting that all the attempts to test his confidence in the investment story have only made him more bullish. 4. Intuit (INTU) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Keith Weiss saying new products, tax code changes and a more benign competitive environment position the company to exceed conservative revenue expectations in FY19. 5. Addus HomeCare (ADUS) upgraded to Outperform from Neutral at Baird with analyst Matthew Gillmor saying he believes secular drivers will support attractive growth and bullish fundamentals for the home care sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/27/19
BMOC
06/27/19
INITIATION
Target $81
BMOC
Market Perform
Addus HomeCare initiated with a Market Perform at BMO Capital
BMO Capital analyst Matt Borsch started Addus HomeCare with a Market Perform rating and $81 price target. The analyst expects the company to continue befitting from favorable demographics, but its "high" business concentration, low barriers of entry, and "premium" valuation keep him on the sidelines with respect to the shares.
AMED Amedisys
$131.66

-3 (-2.23%)

07/12/19
WBLR
07/12/19
NO CHANGE
WBLR
William Blair stays Outperform on Healthcare Delivery names after CMS proposal
The fiscal 2020 Medicare payment and policy proposal for home health agencies was published last night, William Blair analyst Matt Larew tells investors in a research note. He points out that the proposal includes an update on the shift to the "Patient-Driven Groupings Model,"and moves the unit of payment from a 60-day period to a 30-day period. As expected, the language related to the proposed "behavioral adjustment" remained in the proposal, Larew says. The cumulative rate cut that Centers for Medicare and Medicaid Services forecasts to offset assumed behavioral changes increased from 6.42% to 8.01%, largely to account for the number of clinical coding groups moving from six to 12 groups, he notes. However, the estimated 30-day payment after incorporating the behavioral assumptions actually increased slightly from $1,753.68 to $1,754.37, according to the analyst. Larew did not expect the behavioral cuts to be removed in the proposal and believes the "Patient-Driven Groupings Model" itself will prove manageable for large Healthcare Delivery players like Amedisys (AMED), Encompass Health (EHC), and LHC Group (LHCG). The analyst has Outperform ratings on all three. The changes in the rate/dollar calculations were a bit surprising, but the "dollars" are more important than the "rates" and the dollars were unchanged, contends Larew.
08/02/19
RBCM
08/02/19
NO CHANGE
Target $150
RBCM
Outperform
Amedisys price target raised to $150 from $133 at RBC Capital
RBC Capital analyst Frank Morgan raised his price target on Amedisys to $150 after its "strong" Q2 beat, with organic growth seen in both segments and margin expansion in home health offsetting the drag from CCM. The analyst lowers his FY20 EPS view to $4.27 from $4.58, modeling a "more conservative" scenario around Patient Driven Groupings Model but keeps his Outperform rating, saying the company still has "strong capital structure and liquidity position" in place for potential M&A.
08/01/19
OPCO
08/01/19
NO CHANGE
Target $150
OPCO
Outperform
Amedisys price target raised to $150 from $140 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Amedisys to $150 from $140 following quarterly results. The analyst reiterates an Outperform rating on the shares.
07/15/19
RAJA
07/15/19
NO CHANGE
Target $144
RAJA
Outperform
Amedisys price target raised to $144 from 140 at Raymond James
Raymond James analyst John Ransom raised his price target for Amedisys to $144 from $140 and reiterated an Outperform rating following an updated take on the Patient-Driven Groupings Model proposed real and more clarity on how the company might respond. In a research note to investors, Ransom says he is raising his 2020 adjusted EBITDA view by $5M, driven by better home health cost management than expected and double digit growth in non-Medicare HH. Ransom expects HH EBITDA to grow by 6%, and thinks the release of the proposed rule removes the key overhang on shares.
BKD Brookdale Senior Living
$8.02

-0.115 (-1.41%)

10/11/18
SPHN
10/11/18
NO CHANGE
SPHN
Stephens says home health final rule looking like draft would weigh on providers
Stephens analyst Dana Hambly said he expects the final rule for home health reimbursement to be released by CMS in the first week of November. He is concerned that if the final rule looks similar to the draft rule, particularly regarding behavioral assumptions, it would weigh on home health stocks. For-profit, urban providers with higher percentages of therapy visits are estimated to take the largest cuts under a Patient Driven Groupings Model for reimbursement, said Hambly, who sees the impact being largest for Brookdale Senior Living (BKD) and Humana's (HUM) Kindred at Home. Others that may be impacted include Amedisys (AMED), Encompass Health (EHC), Ensign Group (ENSG) and LHC Group (LHCG).
12/27/18
12/27/18
NO CHANGE

Stephens to keep GrubHub, RealPage, Vulcan Materials on 2019 Best Ideas list
Stephens said that it plans to publish a complete updated 2019 Best Ideas list on January 2, but in anticipation it shared the names that are being dropped and the three stocks that will remain on the list. The holdovers are GrubHub (GRUB), RealPage (RP) and Vulcan Materials (VMC). The stocks being removed include Boston Scientific (BSX), Brookdale Senior Living (BKD), Conn's (CONN), CoStar Group (CSGP), Curo Group (CURO), FedEx (FDX), First Financial Bancorp (FFBC), Graphic Packaging (GPK), Hub Group (HUBG), Keane Group (FRAC), KeyCorp (KEY), LKQ Corp. (LKQ), Myriad Genetics (MYGN), SVB Financial (SIVB), Triumph Bancorp (TBK), TrueCar (TRUE) and Union Bankshares (UBSH).
CYH Community Health
$2.12

-0.145 (-6.42%)

12/28/18
PIPR
12/28/18
NO CHANGE
PIPR
Piper says buy Centene, sell Community Health if recession were to occur
After performing a recession risk/reward for Hospitals and Managed Care Organizations, Piper Jaffray analyst Sarah James recommends buying Centene (CNC) and selling Community Health Systems (CYH) if a recession were to occur. The analyst says that with some economists calling for a recession in 2019, she dug into the potential impacts across the hospital and insurance sector. For hospitals, consumer surveys point to economic outlook impacting decisions to receive services, James tells investors in a research note. On the other hand, insurers are a "natural defensive sector in a recession," adds the analyst. As such, in a recession James would be adding exposure to insurers and lightening hospitals.
11/15/18
UBSW
11/15/18
INITIATION
UBSW
HCA Healthcare, Encompass Health, Universal Health initiated with Buy at UBS
UBS analyst Whit Mayo launched coverage of Healthcare Facilities with a broader research note titled "Navigating an Evolving Landscape - Who Will Be Left?". The analyst is most bullish on stocks that "discount the perceived secular sector headwinds" such as Buy-rated HCA Healthcare (HCA), Encompass Health (EHC), and Universal Health (UHS), adding that investors also under-appreciate the accelerating free-cash flow profiles of these companies. Mayo differentiates HCA Healthcare based on its 0% correlation in national hospital utilization trends against public results. The analyst is also bullish on LHC Group (LHCG), stating that its same-property admission growth projections are higher than the rest. Mayo rates Community Health Systems (CYH), DaVita (DVA), and Mednax (MD) at a Sell with a bearish view of dialysis, births, and inpatient surgery end-markets. The analyst sees Community Health Systems same-property volume trend at a relatively low rate. Mayo also gives Acadia (ACHC), Amedisys (AMED), Surgery Partners (SGRY), and Tenet (THC) a Neutral rating as part of this research note based on their relative valuation as a factor of same-property volume growth.
07/10/19
GSCO
07/10/19
UPGRADE
Target $160
GSCO
Buy
Goldman upgrades HCA Healthcare to Buy, boosts priced target to $160
Goldman Sachs analyst Stephen Tanal upgraded HCA Healthcare (HCA) to Buy from Neutral and raised his price target for the shares to $160 from $147. After deep dive of local market competitive dynamics and market share patterns of hospitals, the analyst has a "greater appreciation for the resiliency" of the economic model of certain acute hospitals, notably HCA. The company, and certain other hospital systems, have sufficient bargaining power at the local level to mitigate the effects of any potential negative policy actions taken by government agencies, Tanal tells investors in a research note. The analyst keeps Sell ratings on both Community Health (CYH) and Universal Health (UHS).
04/17/19
SPHN
04/17/19
NO CHANGE
SPHN
Issues facing healthcare sector now 'modest' compared to 2008-10, says Stephens
Stephens analyst Scott Fidel noted that the managed care group has sharply underperformed the S&P 500 over the last month amid "political rhetoric" around point-of-sale drug rebates and Medicare for all policy proposals, though he believes the issues facing the sector right now "seem modest in comparison" to the "dark days of 2008-2010." While recent Medicare for all proposals have rattled investors, "they will face enormous uphill battles," Fidel tells investors. Hospital stocks have outperformed MCOs year-to-date, but the group declined about 9% yesterday and underperformed the MCO group, which Fidel attributes to acknowledgement by industry bellwether UnitedHealth (UNH) of the significant disruptive nature of Medicare for all, which may have sparked additional fears, as well as one less calendar day being called out by UnitedHealth as benefiting Q1 MLRs and Johnson & Johnson's (JNJ) earnings call commentary on declining sequential hospital admissions from Q4. Publicly traded companies in the hospital space include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS). Publicly traded companies in the managed care space include Anthem (ANTM), CVS Health (CVS), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
EHTH eHealth
$104.49

-5.32 (-4.84%)

07/29/19
FANA
07/29/19
UPGRADE
Target $136
FANA
Strong Buy
eHealth upgraded to Strong Buy from Outperform at First Analysis
First Analysis analyst Frank Sparacino upgraded eHealth to Strong Buy from Outperform and raised his price target for the shares to $136 from $106. The analyst cites "another strong quarter and an increased 2019 outlook" for the upgrade, which he notes included the company's core Medicare business growing 51%-58% versus initial projections of 22%-29% growth compared to 2018. He calls eHealth the "leading private online health insurance exchange focused on the Medicare market."
07/26/19
RBCM
07/26/19
NO CHANGE
Target $111
RBCM
Outperform
eHealth price target raised to $111 from $89 at RBC Capital
RBC Capital analyst Frank Morgan raised his price target on eHealth to $111 and kept his Outperform rating after its "impressive" beat-and-raise Q2 results. The analyst cites the the company's marketing strategy and sales execution along with the opportunities within the "attractive" Medicare business. Morgan notes that investments made in growing the existing call centers, boosting staffing, and streamlining technology position eHealth for deeper penetration of online enrollment.
07/26/19
RHCO
07/26/19
NO CHANGE
Target $150
RHCO
Buy
eHealth price target raised to $150 from $120 at SunTrust
SunTrust analyst Tobey Sommer raised his price target on eHealth to $150 and kept his Buy rating after its better than expected Q2 results. The analyst is positive on the company's position as the only platform in the Medicare market where seniors can optimize their health insurance selections and believes that higher online adoption can help it unlock "material margin expansion."
08/06/19
FBCO
08/06/19
NO CHANGE
Target $136
FBCO
Outperform
eHealth price target raised to $136 from $118 at Credit Suisse
Credit Suisse analyst Jailendra Singh raised his price target for eHealth to $136 from $118 as he sees a growth story still in its early stage and given guidance that he believes reflects conservative expectations around external agents' productivity. The analyst reiterates an Outperform rating on the shares.
EHC Encompass Health
$61.49

-0.87 (-1.40%)

07/31/19
PIPR
07/31/19
NO CHANGE
Target $77
PIPR
Overweight
Encompass Health selloff yesterday a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Sarah James lowered her price target for Encompass Health to $77 from $92 but views yesterday's share selloff as a buying opportunity. While sentiment is driven heavily by rates, the larger impact on the earnings potential is growth in the stroke market and effective capital deployment, James tells investors in a post-earnings research note. She believes Encompass is likely to gain share from smaller companies and keeps an Overweight rating on the name.
08/05/19
JEFF
08/05/19
NO CHANGE
Target $80
JEFF
Buy
Encompass Health share selloff 'disconnected' from results, says Jefferies
The post-earnings pullback in shares of Encompass Health is "disconnected from the strong results" and management's "conservative" guidance raise that should lead to EBITDA upside in the second half of 2019, Jefferies analyst Brian Tanquilut tells investors in a research note. The analyst, who recognizes concerns over the company's 2020 earnings power given management's comments about upcoming headwinds, reiterates a Buy rating on Encompass with an $80 price target.
08/12/19
CHLM
08/12/19
NO CHANGE
Target $76
CHLM
Buy
Encompass Health price target lowered to $76 from $81 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich lowered his price target for Encompass Health to $76 from $81 as he believes the company's outlook for Medicare's reimbursement change to the PatientDriven Groupings Model and the proposed 8.01% reduction to the base rate associated with behavioral assumptions is a worst-case scenario and could prove conservative due to proposed legislation. The analyst reiterates a Buy rating on the shares.
HCA HCA Healthcare
$123.22

-4.65 (-3.64%)

07/10/19
GSCO
07/10/19
UPGRADE
Target $160
GSCO
Buy
HCA Healthcare upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Stephen Tanal upgraded HCA Healthcare to Buy from Neutral and raised his price target for the shares to $160 from $147.
07/10/19
07/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Comcast (CMCSA) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Brett Feldman saying he estimates Comcast will sustain "strong growth" over next three years with annual earnings growth of 11%, free cash flow per share of 12% and dividends of 15%, driven by "healthy fundamentals across its key businesses." 2. Total (TOT) upgraded to Outperform from Neutral at Credit Suisse with analyst Thomas Adolff saying he believes the company's Strategy Day in September will serve as a catalyst. 3. DMC Global (BOOM) upgraded to Buy from Neutral at Sidoti. 4. Core Laboratories (CLB) upgraded to Buy from Neutral at BofA/Merrill with analyst Chase Mulvehill saying he sees the stock being set to reverse its outperformance after having fallen 10% year-to-date. 5. HCA Healthcare (HCA) upgraded to Buy from Neutral at Goldman Sachs with analyst Stephen Tanal saying he has a "greater appreciation for the resiliency" of the economic model of certain acute hospitals, notably HCA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/31/19
MZHO
07/31/19
NO CHANGE
Target $153
MZHO
Buy
HCA Healthcare selloff yesterday an overreaction, says Mizuho
Mizuho analyst Ann Hynes views the 9% post-earnings selloff yesterday in shares of HCA Healthcare as an overreaction. Expectations were high for a beat and a meaningful guidance raise going into the Q2 report given the significant outperformance in Q1, and HCA did not meet those expectations, Hynes tells investors in a research note. The analyst, however, does not believe there is any fundamental change to HCA's business. She keeps a Buy rating on the shares with a $153 price target.
SEM Select Medical
$15.87

-0.23 (-1.43%)

05/17/19
JMPS
05/17/19
UPGRADE
Target $18
JMPS
Outperform
Select Medical upgraded to Outperform with $18 price target at JMP Securities
As previously reported, JMP Securities analyst Peter Martin upgraded Select Medical to Outperform from Market Perform following his review of the company's 10Q for the first quarter. He notes the percentage of EBITDA contribution from the Critical Illness division is declining, but the unit is operationally stable. He also contends that the Concentra division, which has seen its average adjusted EBITDA margins expand 200bps over the last 24 months, "could be a cash cow if fueled properly." Martin added that he has become more comfortable with Select's ability to generate the free cash flow needed to meet its Concentra put option obligations in each of the next three years. He set a $18 price target on Select Medical shares.
10/16/18
FBCO
10/16/18
INITIATION
Target $18
FBCO
Neutral
Select Medical initiated with a Neutral at Credit Suisse
Credit Suisse analyst A.J. Rice started Select Medical with a Neutral rating and $18 price target. While the analyst views most of its businesses as normalized 3% top-line growers, he believes the company has an opportunity to push growth higher over the next several years through development of inpatient rehab facilities.
05/17/19
JMPS
05/17/19
UPGRADE
JMPS
Outperform
Select Medical upgraded to Outperform from Market Perform at JMP Securities
12/14/18
LEHM
12/14/18
INITIATION
Target $20
LEHM
Equal Weight
Select Medical initiated with an Equal Weight at Barclays
Barclays analyst Patrick Feeley started Select Medical Holdings with an Equal Weight rating and $20 price target. The fast-growing IRF segment is just 15% of the company's revenue, and the majority of its business segments are low single-digit growers, says the analyst.
SGRY Surgery Partners
$6.22

-0.28 (-4.31%)

09/18/18
BOFA
09/18/18
UPGRADE
BOFA
Buy
Surgery Partners upgraded to Buy from Neutral at BofA/Merrill
09/18/18
BOFA
09/18/18
UPGRADE
Target $20
BOFA
Buy
Surgery Partners upgraded to Buy on volume turnaround at BofA/Merrill
As previously reported, BofA/Merrill upgraded Surgery Partners to Buy from Neutral and maintained a $20 price target. Analyst Kevin Fischbeck believes Surgery Partners' volume turnaround is near an inflection point and expects growth to improve through 2018 and 2019.
11/15/18
UBSW
11/15/18
INITIATION
Target $15
UBSW
Neutral
Surgery Partners initiated with a Neutral at UBS
UBS analyst Whit Mayo initiated Surgery Partners with a Neutral rating and a price target of $15.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
08/22/19
08/22
09:18
08/22/19
09:18
Options
Overnight activity included 448 trades in SPX and 9 trades in VIX »

448 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBIO

Pressure BioSciences

$0.00

(0.00%)

09:17
08/22/19
08/22
09:17
08/22/19
09:17
Hot Stocks
Pressure BioSciences announces two purchase orders for BaroShear K45 system »

Pressure BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOB

Live Oak Bancshares

$18.15

0.03 (0.17%)

09:17
08/22/19
08/22
09:17
08/22/19
09:17
Conference/Events
Live Oak Bancshares management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

CORR

CorEnergy

$45.85

0.95 (2.12%)

09:17
08/22/19
08/22
09:17
08/22/19
09:17
Hot Stocks
CorEnergy announces FERC approval of MoGas rate case »

CorEnergy announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNV

Synovus

$35.54

0.36 (1.02%)

09:16
08/22/19
08/22
09:16
08/22/19
09:16
Conference/Events
Synovus management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 29

    Aug

  • 23

    Sep

BDRBF

Bombardier

$0.00

(0.00%)

09:16
08/22/19
08/22
09:16
08/22/19
09:16
Hot Stocks
Bombardier wins contract to supply, maintain 30 FLEXITY trams in Dresden »

Bombardier Transportation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNO

Terreno Realty

$50.49

-0.03 (-0.06%)

09:15
08/22/19
08/22
09:15
08/22/19
09:15
Hot Stocks
Terreno Realty acquires property in Auburn, WA for $9.5M »

Terreno Realty acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNV

Synovus

$35.54

0.36 (1.02%)

09:15
08/22/19
08/22
09:15
08/22/19
09:15
Conference/Events
Synovus management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 29

    Aug

  • 23

    Sep

VVI

Viad

$67.02

0.99 (1.50%)

09:14
08/22/19
08/22
09:14
08/22/19
09:14
Conference/Events
Viad management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

PLBC

Plumas Bancorp

$23.31

(0.00%)

09:13
08/22/19
08/22
09:13
08/22/19
09:13
Hot Stocks
Plumas Bancorp appoints Heidi Gansert to board of directors »

On August 21, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRL

Hormel Foods

$40.96

0.07 (0.17%)

, DKS

Dick's Sporting

$32.97

0.62 (1.92%)

09:13
08/22/19
08/22
09:13
08/22/19
09:13
Hot Stocks
Fly Intel: Pre-market Movers »

UP AFTER EARNINGS: Hormel…

HRL

Hormel Foods

$40.96

0.07 (0.17%)

DKS

Dick's Sporting

$32.97

0.62 (1.92%)

BJ

BJ's Wholesale

$22.54

0.915 (4.23%)

FLWS

1-800-Flowers.com

$19.36

0.74 (3.97%)

FLY

Fly Leasing

$18.25

0.265 (1.47%)

JWN

Nordstrom

$26.51

1.38 (5.49%)

KEYS

Keysight Technologies

$89.14

1.85 (2.12%)

WUBA

58.com

$56.06

0.83 (1.50%)

RTRX

Retrophin

$17.39

0.3 (1.76%)

SQM

SQM

$25.40

-0.86 (-3.27%)

SEDG

SolarEdge

$87.87

3.16 (3.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 03

    Sep

  • 05

    Sep

  • 10

    Sep

  • 10

    Sep

  • 15

    Sep

  • 24

    Sep

  • 25

    Sep

  • 01

    Oct

ASH

Ashland

$73.07

0.83 (1.15%)

09:12
08/22/19
08/22
09:12
08/22/19
09:12
Conference/Events
Ashland management to meet with SunTrust »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 27

    Aug

FTS

Fortis

$41.21

0.19 (0.46%)

09:10
08/22/19
08/22
09:10
08/22/19
09:10
Downgrade
Fortis rating change at CIBC »

Fortis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 11

    Nov

APEX

Apex Global Brands

$0.52

-0.0187 (-3.47%)

09:10
08/22/19
08/22
09:10
08/22/19
09:10
Hot Stocks
Apex Global Brands expands Tony Hawk brand through licensing agreements »

APEX Global Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JE

Just Energy

$1.19

-0.14 (-10.57%)

09:10
08/22/19
08/22
09:10
08/22/19
09:10
Upgrade
Just Energy rating change  »

Just Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:10
08/22/19
08/22
09:10
08/22/19
09:10
General news
Fedspeak from Jackson Hole: »

Fedspeak from Jackson…

AOSL

Alpha & Omega

$12.84

0.06 (0.47%)

09:10
08/22/19
08/22
09:10
08/22/19
09:10
Recommendations
Alpha & Omega analyst commentary at Loop Capital »

Alpha & Omega price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 11

    Sep

  • 12

    Sep

RBZ

Reebonz Holding

$2.20

0.42 (23.60%)

09:09
08/22/19
08/22
09:09
08/22/19
09:09
Hot Stocks
Reebonz Holding announces sell back guarantee data »

Reebonz Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPG

Washington Prime

$3.31

0.07 (2.16%)

09:08
08/22/19
08/22
09:08
08/22/19
09:08
Conference/Events
Washington Prime management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

DKS

Dick's Sporting

$32.97

0.62 (1.92%)

09:08
08/22/19
08/22
09:08
08/22/19
09:08
Hot Stocks
Dick's Sporting sells Affinity Sports, Blue Sombrero to Stack Sports »

Stack Sports announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

SEEL

Seelos Therapeutics

$1.66

-0.03 (-1.78%)

09:07
08/22/19
08/22
09:07
08/22/19
09:07
Hot Stocks
Seelos Therapeutics announces FDA acceptance of IND application for SLS-005 »

Seelos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

$228.75

3 (1.33%)

09:06
08/22/19
08/22
09:06
08/22/19
09:06
Conference/Events
Air Products management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

TGT

Target

$103.11

17.54 (20.50%)

09:06
08/22/19
08/22
09:06
08/22/19
09:06
Recommendations
Target analyst commentary at Credit Suisse »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

LRAD

LRAD Corporation

$3.64

0.195 (5.66%)

09:05
08/22/19
08/22
09:05
08/22/19
09:05
Hot Stocks
LRAD Corporation announces $1M in new defense orders »

LRAD Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWOU

2U

$18.60

0.21 (1.14%)

09:05
08/22/19
08/22
09:05
08/22/19
09:05
Hot Stocks
2U announces retirement of CFO Catherine Graham »

2U announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.